Label-free microscopic assessment of glioblastoma biopsy specimens prior to biobanking [corrected]

Document Type

Article

Abstract

Glioblastoma is the most common primary brain tumor with a median 12- to 15-month patient survival. Improving patient survival involves better understanding the biological mechanisms of glioblastoma tumorigenesis and seeking targeted molecular therapies. Central to furthering these advances is the collection and storage of surgical biopsies (biobanking) for research. This paper addresses an imaging modality, confocal reflectance microscopy (CRM), for safely screening glioblastoma biopsy samples prior to biobanking to increase the quality of tissue provided for research and clinical trials. These data indicate that CRM can immediately identify cellularity of tissue biopsies from animal models of glioblastoma. When screening fresh human biopsy samples, CRM can differentiate a cellular glioblastoma biopsy from a necrotic biopsy without altering DNA, RNA, or protein expression of sampled tissue. These data illustrate CRM's potential for rapidly and safely screening clinical biopsy samples prior to biobanking, which demonstrates its potential as an effective screening technique that can improve the quality of tissue biobanked for patients with glioblastoma.

Medical Subject Headings

Animals; Biological Specimen Banks (standards); Biopsy; Brain Neoplasms (pathology); Cell Line, Tumor; Glioblastoma (pathology); Humans; Microscopy, Confocal (methods); Rats; Rats, Nude; Xenograft Model Antitumor Assays (methods)

Publication Date

2-1-2014

Publication Title

Neurosurgical focus

E-ISSN

1092-0684

Volume

36

Issue

2

First Page

E8

PubMed ID

24484261

Digital Object Identifier (DOI)

10.3171/2013.11.FOCUS13478

Link to Full Text

Share

COinS